Science Translational Medicine · 2021 · 116 citations · 72 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy For Solid TumorsPharmacodynamics Of ImmunotherapiesTumor-associated AntigensCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesCd8 Positive T CellsImmune Checkpoint Blockade CombinationsImmune Checkpoint Blockade SynergyImmune Checkpoint Inhibitor TherapySyngeneic Tumor ModelsT Cell Checkpoint Inhibition
T cells, rather than their recruitment from circulation. Our findings highlight the relative contributions of baseline T cell infiltration, local T cell proliferation, and peripheral T cell trafficking for BiTE molecule-mediated efficacy, identify combination strategies capable of overcoming resistance to BiTE therapy, and have clinical relevance for the development of BiTE and other T cell engager therapies.
72
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations
Medicine, Immunology, Oncology +16
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text
Medicine, Immunology, Oncology +17
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin et al. · New England Journal of Medicine · 2016 · 3.2K citations · Full text
Medicine, Immunology, Oncology +17